Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Sella

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
European Journal of Cancer Care|March 26, 2014
Insights into cancer surveillance in Central and Eastern Europe, Israel and TurkeyE Vrdoljak, L Torday, A Sella, et al.
The Journal of Urology|January 1, 1993
Surgery following response to interferon-alpha-based therapy for residual renal cell carcinomaA Sella, D A Swanson, J Y Ro, et al.
American Journal of Clinical Pathology|October 1, 1994
Tubular seminoma. An immunohistochemical and DNA flow-cytometric study of four casesA Zavala-Pompa, J Y Ro, A K el-Naggar, et al.
The Journal of Urology|September 1, 1991
Circadian infusion of floxuridine in patients with metastatic renal cell carcinomaF H Dexeus, C J Logothetis, A Sella, et al.
Bioorganic & Medicinal Chemistry|April 28, 1999
Inhibition of adamalysin II and MMPs by phosphonate analogues of snake venom peptidesS D'Alessio, C Gallina, E Gavuzzo, et al.
Cancer|December 10, 1997
Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinomaJ A Ellerhorst, A Sella, R J Amato, et al.
The Journal of Urology|October 1, 1991
Evidence of malignant features in histologically mature teratomaA Sella, A el Naggar, J Y Ro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trialC J Logothetis, L D Finn, T Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancerC N Sternberg, H Dumez, H Van Poppel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an updateC J Logothetis, D E Johnson, C Chong, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
European Journal of Cancer Care|March 26, 2014
Insights into cancer surveillance in Central and Eastern Europe, Israel and TurkeyE Vrdoljak, L Torday, A Sella, et al.
The Journal of Urology|January 1, 1993
Surgery following response to interferon-alpha-based therapy for residual renal cell carcinomaA Sella, D A Swanson, J Y Ro, et al.
American Journal of Clinical Pathology|October 1, 1994
Tubular seminoma. An immunohistochemical and DNA flow-cytometric study of four casesA Zavala-Pompa, J Y Ro, A K el-Naggar, et al.
The Journal of Urology|September 1, 1991
Circadian infusion of floxuridine in patients with metastatic renal cell carcinomaF H Dexeus, C J Logothetis, A Sella, et al.
Bioorganic & Medicinal Chemistry|April 28, 1999
Inhibition of adamalysin II and MMPs by phosphonate analogues of snake venom peptidesS D'Alessio, C Gallina, E Gavuzzo, et al.
Cancer|December 10, 1997
Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinomaJ A Ellerhorst, A Sella, R J Amato, et al.
The Journal of Urology|October 1, 1991
Evidence of malignant features in histologically mature teratomaA Sella, A el Naggar, J Y Ro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trialC J Logothetis, L D Finn, T Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancerC N Sternberg, H Dumez, H Van Poppel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an updateC J Logothetis, D E Johnson, C Chong, et al.
Pageof 9